Cidara Therapeutics Inc share price logo

Cidara Therapeutics Inc Share Price

NASDAQ: CDTX

Small Cap

$217.72

+111.73

(+105.42%)

Live

as on

Cidara Therapeutics Inc Stock Performance

as on November 14, 2025 at 8:39 pm IST

  • Day's Low

    Day's High

    $216.8
    $218
    downward going graph

    0.42%

    Downside

    0.13%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $13.82
    $121.21
    downward going graph

    93.65%

    Downside

    -44.33%

    Upside

    downward going graph

Cidara Therapeutics Inc share price movements today

Previous Close
$105.99
Open
$217.57
Volume
4.2M
Day's Low - High
$216.8 - $218
52 Week Low - High
$13.82 - $121.21

Cidara Therapeutics Inc Historical Returns

1 Month Return
-4.2 %
3 Month Return
+ 66.78 %
1 Year Return
+ 631.98 %
3 Year Return
+ 806.83 %
5 Year Return
+ 108.64 %

Cidara Therapeutics Inc Stock Fundamentals & Key Indicators

Check Cidara Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.4B

EPS (TTM)

-7.334

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.8

Industry PE ratio

0

PEG Ratio

0

EBITDA

-159.8M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-68.70%

Cidara Therapeutics Inc Stock Valuation

Track how Cidara Therapeutics Inc P/E has moved over time to understand its valuation trends.

Cidara Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (-180.77x)

June 30, 2023

Industry (0.00x)

November 14, 2025

Today (-0.80x)

November 14, 2025

Highest (-0.48x)

September 30, 2024

LowHigh

Today’s Price to Earnings Ratio: -0.80x

Cidara Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cidara Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Cidara Therapeutics Inc image
Cidara Therapeutics Inc
BUY$3.4B108.64%-0.80.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$59.8B235.01%1414.811.36%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$40.9BNA712.211.38%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$110.2B92.67%30.5831.35%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$71.6B22.7%16.3432.13%

Stock Returns calculator for Cidara Therapeutics Inc Stock including INR - Dollar returns

The Cidara Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Cidara Therapeutics Inc investment value today

Current value as on today

₹15,08,786

Returns

₹14,08,786

(+1.41K%)

Returns from Cidara Therapeutics Inc Stock

₹14,03,591 (+1.4K%)

Dollar Returns*

₹5,194 (+5.19%)

Analyst Recommendation on Cidara Therapeutics Inc Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Cidara Therapeutics Inc. Average target price of $160.71

Cidara Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Cidara Therapeutics Inc.

What analysts predicted

-35.47%DOWNSIDE

Target Price

$160.71

Current Price

$217.72

Analyzed by

10 Analysts

Target

$160.71

Cidara Therapeutics Inc target price $160.71, a slight downside of -35.47% compared to current price of $217.72. According to 10 analysts rating.

Cidara Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Cidara Therapeutics Inc Stock has decreased by -20% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-20% versus previous 30 day period

Cidara Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
5
12
17
8
0
-
-
-
-
-
Gross Profit
5
12
16
6
0
0
-90
0
0
-45
Operating Income
-6
-4
-6
-10
-95
-17
-54
-25
-27
-88
EBITDA
-6
-3
-
-10
-11
-17
-54
-25
-27
-83
Interest Expense
0
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-6
-3
-5
-10
-94
-15
-52
-23
-25
-83
Income Tax Expense
0
0
-
0
-4
-
-
-
-
-
Net Income
-13
-8
-5
-10
-91
-15
-52
-23
-25
-83
Net Profit Margin
-267.66%
-64.26%
-31.91%
-122.01%
-30201.66%
0.00%
0.00%
0.00%
0.00%
0.00%

Cidara Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
-
-
20
12
49
64
23
1
Gross Profit
0
0
-42
0
-25
12
49
64
-13
1
Operating Income
-32
-48
-55
-63
-41
-71
-42
-29
-27
-176
EBITDA
-31
-47
-55
-62
-41
-70
-43
-28
-26
-175
Interest Expense
0
0
0
0
0
0
0
0
-
-
Depreciation
-
-
0
0
0
0
-1
1
0
0
Income Before Tax
-32
-48
-55
-59
-41
-72
-42
-29
-25
-170
Income Tax Expense
0
0
0
4
-1
0
1
0
0
-
Net Income
-32
-48
-55
-59
-41
-72
-43
-29
-22
-169
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
-196.47%
-597.59%
-88.58%
-46.35%
-98.49%
-13319.76%

Cidara Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Net Income
-8
-3
-10
-89
-12
-52
-23
-25
-83
Operating Cash Flow
-1
-12
-6
-103
-36
-29
-21
-40
-40
Investing Cash Flow
0
-
0
-
0
-
0
-
-176
Financing Cash Flow
8
0
0
239
0
98
0
383
0
Change in Cash
-1
-12
-6
135
-36
68
-21
342
-216

Cidara Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-48
-55
-59
-41
-72
-42
-29
-22
-169
Operating Cash Flow
-39
-49
-56
-28
-54
-25
-28
-22
-176
Investing Cash Flow
25
4
14
0
0
0
0
0
0
Financing Cash Flow
37
20
56
14
37
44
0
25
337
Change in Cash
22
-24
13
-14
-17
19
-29
3
160

Global Institutional Holdings in Cidara Therapeutics Inc

Funds
Holdings
RA Capital Management, LLC
13.27%
Bain Capital Life Sciences Investors, LLC
9.86%
Point72 Asset Management, L.P.
6.03%
Vivo Capital, LLC
5.17%
COMMODORE CAPITAL LP
4.63%
See all

Cidara Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 14 November

    Fri, 05:15 PM

    -

    Merck's acquisition of Cidara represents a transformational moment for the company and its influenza prevention mission.

    Fri, 06:02 PM

    -

    Merck's acquisition of Cidara includes a lead antiviral candidate currently in Phase 3 studies.

    Fri, 06:30 PM

    -

    Cidara stock rose significantly after Merck's acquisition announcement, with a 109% premium over previous closing price.

  • img

    Today's Timeline - 14 November

    Fri, 06:51 PM

    -

    Merck to pay $221.50 per share for Cidara, totaling $9.2 billion, pending shareholder approval.

    Fri, 07:05 PM

    -

    Cidara shares surged 103% after Merck agreed to acquire the company for approximately $9.2 billion in cash.

Insights on Cidara Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, CDTX stock has moved up by 449.0%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, CDTX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, CDTX has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 17.58M → 302.0K (in $), with an average decrease of 74.2% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -23.48M → -83.23M (in $), with an average decrease of 116.6% per quarter

About Cidara Therapeutics Inc

cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
OrganisationCidara Therapeutics Inc
Headquarters6310 Nancy Ridge Drive, San Diego, CA, United States, 92121
IndustryHealth Technology
CEODr. Jeffrey L. Stein Ph.D.
E-voting on sharesClick here to vote

Key Management of Cidara Therapeutics Inc

Name

Title

Mr. Jim Beitel M.B.A.

Chief Business Officer

Dr. Leslie Tari Ph.D.

Chief Scientific Officer

Dr. Kevin M. Forrest Ph.D.

Founder & Chief Strategy Officer

Mr. Shane M. Ward J.D.

COO & Corporate Secretary

Ms. Allison Lewis CCP, SPHR

Senior Vice President of People & Culture

Dr. Nicole Davarpanah J.D., M.D.

Chief Medical Officer

Dr. Jeffrey L. Stein Ph.D.

President, CEO & Executive Director

Mr. Frank L. Karbe M.B.A.

Chief Financial Officer

Dr. Preetam Shah M.B.A., Ph.D.

Principal Accounting Officer

Ms. Corrina Pavetto

Senior Vice President of Clinical Development

FAQs

What is Cidara Therapeutics Inc share price today?

Cidara Therapeutics Inc share price today is $217.72 as on . Cidara Therapeutics Inc share today touched a day high of $218 and a low of $216.8.

What is the 52 week high and 52 week low for Cidara Therapeutics Inc share?

Cidara Therapeutics Inc share touched a 52 week high of $121.21 on and a 52 week low of $13.82 on . Cidara Therapeutics Inc stock price today i.e. is trending at $217.72,which is -79.62% down from its 52 week high and 1475.40% up from its 52 week low.

What is Cidara Therapeutics Inc's market capitalisation today?

Cidara Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Cidara Therapeutics Inc Stock (CDTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Cidara Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cidara Therapeutics Inc Shares that will get you 0.0069 shares as per Cidara Therapeutics Inc share price of $217.72 per share as on November 14, 2025 at 8:39 pm IST.

What is the minimum amount required to buy Cidara Therapeutics Inc Stock (CDTX) from India?

Indian investors can start investing in Cidara Therapeutics Inc (CDTX) shares with as little as ₹88.7 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹887.00 in Cidara Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Cidara Therapeutics Inc share’s latest price of $217.72 as on November 14, 2025 at 8:39 pm IST, you will get 0.0459 shares of Cidara Therapeutics Inc. Learn more about fractional shares .

What are the returns that Cidara Therapeutics Inc has given to Indian investors in the last 5 years?

Cidara Therapeutics Inc stock has given 108.64% share price returns and 19.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?